Compound class

GLP-1 and incretin compounds

Compounds that act on gut hormone receptors, from semaglutide to retatrutide.

Each figure is as the compound's own sources give it, numbered under References. Where they give none, the list says not stated. The half-life the app draws levels with can differ. Reviewed 17 November 2026.

Most compounds here are agonists of the GLP-1 receptor, such as semaglutide.1 Tirzepatide also acts on the GIP receptor,2 and cagrilintide is an amylin analogue.3 Tirzepatide is a once-weekly injection,2 orforglipron is a tablet,4 and eloralintide is still under development.5

GLP-1 and incretin agonists 8

Amylin and GLP-2 4

Half-lives side by side

The figure each source gives, on one scale. Bars are ranges.

  • Teduglutide (GLP-2)about 2 h
  • Exenatide2.4 h, Byetta
  • Liraglutideabout 13 h
  • Orforglipronabout 29 to 49 h
  • Dulaglutideabout 5 days
  • Tirzepatideabout 5 days
  • Retatrutideabout 6 days
  • Cagrilintide159 to 195 h, with semaglutide
  • Semaglutideabout 1 week

Log scale, 1 hour to about 3 weeks. Each figure and its source are in the list above. Minutes, days and weeks are turned into hours (1 day is 24 hours) only to place them on the scale. These are the sources' figures; the half-life the app uses to draw levels can differ.

Guides 11

Calculators 6

Compare 4

Logged in Milligram

Share of people who logged a dose in Milligram in the 90 days to 15 November 2026 who logged each compound.

  • Retatrutide49%
  • Tirzepatide5%

Retatrutide, how often

  • Daily6%
  • Every other day7%
  • Twice a week29%
  • Weekly52%
  • Less often6%

Tirzepatide, how often

  • Daily6%
  • Every other day10%
  • Twice a week8%
  • Weekly68%
  • Less often8%

How often: among people with three or more logged doses, by the average gap between their doses.

Aggregated and anonymous, shares of people only. Each compound not listed: too few people logged it to show a share. It describes what people set up in the app, not advice on what to take.

References 15

  1. Novo Nordisk Pharmaceutical Industries, LP. OZEMPIC (semaglutide) injection, for subcutaneous use. Prescribing information, Novo Nordisk. 2026. DailyMed label
  2. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing information, revised August 2026. 2026. DailyMed label
  3. Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. 2021. PMID 34798060
  4. Eli Lilly and Company. FOUNDAYO (orforglipron) label, version 10. 2026. DailyMed label
  5. Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. 2026. PMC12992164
  6. Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 2022. PMID 36354040
  7. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med 2026. PMID 42814954
  8. Eli Lilly and Company. Trulicity (dulaglutide) injection, for subcutaneous use. US prescribing information, DailyMed version 62, 2026. DailyMed label
  9. AstraZeneca Pharmaceuticals LP. Byetta (exenatide) injection, for subcutaneous use. US prescribing information, DailyMed version 26, 2025. Byetta label
  10. Bydureon BCise (exenatide extended-release) injectable suspension, for subcutaneous use. US prescribing information, FDA label supplement 209210s025, 2025. Bydureon BCise label
  11. VICTOZA (liraglutide) injection, for subcutaneous use. Prescribing information. Novo Nordisk, 2025. DailyMed label
  12. Aroda VR, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care 2019;42(9):1724-1732. PMID 31186300
  13. Novo Nordisk. Rybelsus (semaglutide) tablets and Ozempic (semaglutide) tablets, for oral use. US prescribing information, DailyMed record, version 14, 2026. DailyMed label (Rybelsus and Ozempic tablets)
  14. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021. PMID 33894838
  15. Takeda Pharmaceuticals America. Gattex (teduglutide) for injection, for subcutaneous use. US prescribing information, DailyMed version 20, 18 September 2025. DailyMed label

Each figure is as the compound's own sources give it, numbered under References. Where they give none, the list says not stated. The half-life the app draws levels with can differ. Reviewed 17 November 2026.